Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +0.75% | -1.47% | +8.06% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Financials (USD)
Sales 2024 * | 189M | Sales 2025 * | 164M | Capitalization | 278M |
---|---|---|---|---|---|
Net income 2024 * | -70M | Net income 2025 * | -116M | EV / Sales 2024 * | 1.48 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.69 x |
P/E ratio 2024 * |
-4.59
x | P/E ratio 2025 * |
-4.64
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.79% |
Latest transcript on Akebia Therapeutics, Inc.
1 day | +0.75% | ||
1 week | -1.47% | ||
Current month | -26.78% | ||
1 month | -40.18% | ||
3 months | -25.14% | ||
6 months | +59.50% | ||
Current year | +8.06% |
Managers | Title | Age | Since |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
Director/Board Member | 65 | 21-02-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.34 | +0.75% | 2,474,352 |
24-04-25 | 1.33 | -2.92% | 2,561,124 |
24-04-24 | 1.37 | 0.00% | 1,535,781 |
24-04-23 | 1.37 | +0.74% | 2,108,817 |
24-04-22 | 1.36 | 0.00% | 2,006,106 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.06% | 278M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- AKBA Stock